Jpmorgan Chase & CO Inhibrx, Inc. Transaction History

Jpmorgan Chase & CO

$1.1 Trillion
Q1 2024

A detailed history of Jpmorgan Chase & CO transactions in Inhibrx, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 72,764 shares of INBX stock, worth $1.03 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

72,764

Previous 51,526 41.22%

Holding current value

$1.03 Million

Previous $1.96 Million 29.94%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$32.76 - $39.56 $695,756 - $840,175	21,238 Added 41.22%	72,764 $2.54 Million
Q4 2023 Feb 12, 2024	SELL	$14.5 - $38.0 $4.62 Million - $12.1 Million	-318,459 Reduced 86.07%	51,526 $1.96 Million
Q3 2023 Nov 14, 2023	BUY	$15.75 - $26.31 $48,636 - $81,245	3,088 Added 0.84%	369,985 $6.79 Million
Q2 2023 Aug 11, 2023	BUY	$16.96 - $27.82 $5.54 Million - $9.09 Million	326,919 Added 817.75%	366,897 $9.52 Million
Q1 2023 May 18, 2023	BUY	$18.45 - $27.14 $731,985 - $1.08 Million	39,674 Added 13050.66%	39,978 $754,000

Q1 2023 May 11, 2023	SELL	$18.45 - $27.14 $589,791 - $867,584	-31,967 Reduced 99.06%	304 $5,000
Q4 2022 Feb 13, 2023	BUY	$20.18 - $33.33 $69,580 - $114,921	3,448 Added 11.96%	32,271 $795,000
Q3 2022 Nov 14, 2022	BUY	$11.58 - $24.73 $40,391 - $86,258	3,488 Added 13.77%	28,823 $517,000
Q2 2022 Aug 11, 2022	BUY	$8.52 - $25.26 $14,662 - $43,472	1,721 Added 7.29%	25,335 $288,000
Q1 2022 May 11, 2022	SELL	$19.89 - $43.18 $749,892 - $1.63 Million	-37,702 Reduced 61.49%	23,614 $527,000
Q4 2021 Feb 10, 2022	BUY	$26.75 - $46.02 $987,208 - $1.7 Million	36,905 Added 151.18%	61,316 $2.68 Million
Q3 2021 Nov 12, 2021	BUY	$25.18 - $37.81 $614,668 - $922,979	24,411 New	24,411 $813,000

Others Institutions Holding INBX

# of Institutions

132

Shares Held

35.5M

Call Options Held

64.8K

Put Options Held

91.3K

View Full List

About Inhibrx, Inc.

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $553M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

More about INBX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Inhibrx, Inc. Transaction History